CJC-1295 DAC dosage calculator: how the math works

Last updated 2026-07-26

What does a CJC-1295 DAC dosage calculator actually calculate?

A CJC-1295 DAC dosage calculator takes three inputs, the amount of peptide in the vial (usually 2 mg or 5 mg), the amount of bacteriostatic water you add, and your target dose, and spits out how many units to draw on an insulin syringe. That's the whole job. It's arithmetic, not medical advice, and it can't tell you whether a given dose is appropriate for your situation. The formula underneath is simple concentration math: concentration (mcg/mL or mcg/unit) = total peptide (mcg) ÷ total reconstitution volume (mL). If you put 2 mg (2000 mcg) of CJC-1295 DAC into 2 mL of bacteriostatic water, you get 1000 mcg/mL, or 10 mcg per unit on a standard U-100 insulin syringe (100 units = 1 mL). So if your target dose is 2000 mcg (2 mg) per week, split into two 1000 mcg doses, that's 100 units per shot on that dilution, which is inconveniently large for an insulin syringe. Most people reconstitute with less water to concentrate the dose, or use a smaller total weekly amount split across two injections of roughly 60 to 100 units, depending on the exact protocol. The calculator's only real value is removing the arithmetic error, not endorsing a specific dose. There's no FDA-approved product here to check dosing against; CJC-1295 has never been approved as a human drug in the US, and it appears on FDA's list of bulk drug substances nominated for use in compounding that the agency placed in Category 2, meaning it identified significant safety concerns and does not recommend it for compounding under section 503A ^[1]. Before touching any calculator, it's worth reading the underlying pharmacology on our cjc 1295 overview, because the number a calculator gives you is only as good as the target dose you feed it.

How much CJC-1295 DAC should I actually take per week?

There is no approved human dose for CJC-1295 DAC because it isn't an approved drug. What exists is a range that shows up consistently across compounding pharmacy references, veterinary/research literature discussions, and the original pharmacology paper on the modified GHRH molecule, generally landing between 1 mg and 2 mg per week, often split into two doses of 0.5 to 1 mg roughly 3 to 4 days apart. The pharmacokinetic reasoning behind that spacing comes from the drug's own development data. The 2006 study by Teichman et al. in the Journal of Clinical Endocrinology & Metabolism, which described the modified GRF(1-29) molecule conjugated to a drug affinity complex (the "DAC" in the name), found the compound had an elimination half-life of approximately 6.8 days in the single-dose portion of the study and produced sustained increases in GH and IGF-1 for at least 6 days after a single injection at doses of 30 to 480 mcg/kg ^[2][3]. Scaled to a roughly 75 kg adult, 60 mcg/kg would be about 4.5 mg, far above what most protocols outside that trial use, which is a reminder that the study doses don't map cleanly onto the small, twice-weekly amounts common in real-world use. That's the core tension: the only controlled human data on this exact molecule used doses and monitoring most self-directed users aren't replicating. Anything below or above the study's dose range, including the 1 to 2 mg/week figures that circulate widely, is extrapolation, not confirmed clinical practice. For a fuller breakdown of where these numbers come from and how they compare across sources, see our dedicated cjc 1295 dosage page.

CJC-1295 DAC vs no-DAC: does the dosage math change?

Yes, substantially, because the two forms have completely different half-lives and are dosed on different schedules. This is one of the most confused points in forum discussions, and it matters for anyone trying to use a calculator correctly. CJC-1295 without DAC (sometimes sold as "Mod GRF 1-29") has a short half-life, commonly cited around 30 minutes, based on the same class of GHRH analogue pharmacokinetics described in the Teichman paper's comparison data ^[2]. Because it clears fast, it's typically dosed daily, often once or twice a day, timed around fasting states or before bed, at doses in the range of 100 to 300 mcg per injection in compounding and research literature. CJC-1295 with DAC has the drug affinity complex attached, which binds to albumin in the blood and dramatically extends its presence, giving that roughly 6.8-day half-life ^[2][3]. That's why DAC protocols use 1 to 2 mg total per week instead of daily microgram doses. A dosage calculator needs to know which version you're calculating for, because plugging a no-DAC daily dose into a DAC weekly schedule (or vice versa) will produce numbers that are wrong by an order of magnitude. | Feature | CJC-1295 (no DAC) | CJC-1295 with DAC |

How do I convert mg to mcg and units correctly?

This trips people up constantly, so it's worth being explicit. 1 milligram (mg) equals 1000 micrograms (mcg). Vials are usually labeled in mg (2 mg, 5 mg), but doses are usually discussed in mcg (250 mcg, 500 mcg, 1000 mcg), and syringes are marked in units, where a standard U-100 insulin syringe has 100 units per 1 mL. The conversion chain is: mg on the vial → mcg total → mcg/mL after reconstitution → mcg per unit → units to draw for your target dose. Worked example: a 2 mg vial reconstituted with 2 mL of bacteriostatic water gives 1000 mcg/mL. Since 1 mL = 100 units, that's 10 mcg per unit. A 500 mcg dose would be 50 units. A 1000 mcg (1 mg) dose would be the full 100 units, the entire mL. Worked example with less water: the same 2 mg vial reconstituted with 1 mL gives 2000 mcg/mL, or 20 mcg per unit. A 500 mcg dose is now only 25 units, a 1000 mcg dose is 50 units. Less water means less volume per dose, which is often preferred for a peptide dosed only once or twice weekly, since it keeps the injection volume small. A calculator's real utility is doing this conversion instantly and letting you sanity-check it by hand at least once, because unit-to-mcg errors are the single most common mistake in self-directed peptide use, and they're a 10x or 100x error, not a rounding error.

How does reconstitution volume change the numbers?

The amount of bacteriostatic water you add is the single biggest lever in the whole calculation, and it's also the one users have the most control over. More water means a lower concentration and a bigger injection volume per dose; less water means a higher concentration and a smaller volume. For a 2 mg vial: 2 mL water → 1000 mcg/mL → 10 mcg/unit 1 mL water → 2000 mcg/mL → 20 mcg/unit 0.5 mL water → 4000 mcg/mL → 40 mcg/unit For a 5 mg vial: 2 mL water → 2500 mcg/mL → 25 mcg/unit 1 mL water → 5000 mcg/mL → 50 mcg/unit There's a practical tradeoff. Too little water and the dose per unit gets so concentrated that small syringe-drawing errors (missing the line by 1-2 units) become large dosing errors in absolute mcg terms. Too much water and you're injecting a larger, sometimes uncomfortable, subcutaneous volume, and you go through vials faster relative to the number of doses you can draw precisely. Most compounding references and peptide-specific storage guidance suggest reconstituting to a concentration that lands your typical single dose somewhere between 20 and 60 units, which is easy to read accurately on a standard syringe. Bacteriostatic water itself matters for another reason entirely: it contains 0.9% benzyl alcohol as a preservative, which is why multi-dose vials reconstituted with it are commonly given a reference shelf life of about 28 days refrigerated once opened, a figure drawn from general USP-based multi-dose vial handling practice rather than peptide-specific stability testing ^[4].

Why is CJC-1295 DAC almost always paired with ipamorelin?

The pairing shows up constantly because the two peptides act on different receptors that both drive GH release, and the theoretical rationale (not a proven clinical outcome) is that combining them produces a larger GH pulse than either alone. CJC-1295 is a GHRH analogue, working through the GHRH receptor; ipamorelin is a ghrelin receptor agonist, working through a separate pathway in the same functional class of GH secretagogues that includes the FDA-approved diagnostic agent macimorelin ^[5]. The mechanistic logic for combining a GHRH analogue with a ghrelin-receptor agonist comes from older growth hormone physiology research showing the two pathways can have additive or synergistic effects on GH pulse amplitude in controlled settings, which is part of why GHRH/GHRP combination protocols exist at all in research contexts. But there is no large controlled human trial of the specific combination of CJC-1295 DAC plus ipamorelin measuring hard outcomes like body composition or long-term IGF-1 safety. What gets cited as support is almost entirely mechanistic reasoning plus each peptide's individual pharmacology, not a dedicated combination trial. Ipamorelin was studied on its own in humans, including a randomized trial in postoperative patients evaluating its GH-releasing effect and safety profile in a hospital setting, published in the Journal of Clinical Endocrinology & Metabolism in 1998 ^[6], but that trial didn't test it alongside CJC-1295 DAC. So the combination that dominates online protocols is a reasonable hypothesis, and it is also, honestly, ahead of the dedicated evidence for the specific pairing. Anyone calculating a combined dosage schedule should treat the ipamorelin timing (usually daily, since it also has a short half-life) as a separate calculation from the once-or-twice-weekly DAC schedule, not a single combined number.

What's folklore and what's actual evidence in CJC-1295 dosing?

This distinction matters more here than almost anywhere else in the peptide space, because so much of the specific dosing lore originated on bodybuilding forums in the mid-2000s and has been repeated so often it now reads as settled fact. What's actually documented: the Teichman 2006 study is the primary human pharmacokinetic and pharmacodynamic data on CJC-1295 DAC, run in healthy adults across single and multiple-dose phases, showing dose-dependent GH and IGF-1 increases and the multi-day half-life ^[2][3]. That's real, peer-reviewed, and it's the foundation everything else builds on, or claims to build on. What's folklore: specific claims about "optimal" weekly totals like exactly 2 mg, claims about ideal injection timing relative to meals or sleep cycles for the DAC version specifically (this timing logic comes from no-DAC GHRH pulsatility research and doesn't obviously transfer to a sustained-release DAC profile), claims that combining CJC-1295 DAC with ipamorelin produces effects proportionally larger than either alone in humans (not directly tested in combination), and most claims about fat loss or muscle gain magnitude, which come from user reports, not controlled trials. Also worth naming plainly: CJC-1295 is not FDA-approved for any human use, isn't recommended for 503A compounding under FDA's own bulk substance review ^[1], and any material sold for research use only that ends up being self-administered sits outside any regulatory safety monitoring that would normally catch dosing problems, adverse events, or contamination early. A calculator giving you a clean number doesn't change that regulatory reality.

How do I use a CJC-1295 DAC dosage calculator step by step?

Here's the practical sequence, whether you're using a web tool or doing it on paper. 1. Confirm the vial size in mg (check the label or certificate of analysis, if one exists). 2. Decide reconstitution volume in mL of bacteriostatic water. Common choices are 1 mL or 2 mL for a 2 mg vial. 3. Calculate concentration: total mcg ÷ mL = mcg/mL. 4. Convert to mcg/unit: mcg/mL ÷ 100 = mcg/unit (since 1 mL = 100 units on a standard insulin syringe). 5. Decide your target single dose in mcg (not the weekly total, the per-injection amount). 6. Divide target dose by mcg/unit to get units to draw: target mcg ÷ mcg/unit = units. 7. Cross-check with a second method, either a second calculator or hand math, before drawing anything into a syringe. A calculator automates steps 3, 4, and 6. It cannot do step 5 for you responsibly, and no legitimate one should pretend to give personalized medical dosing advice. If a tool skips straight from "how much do you want to take" to a number without showing the mcg/mL math, that's a red flag, not a convenience.

What mistakes do people make with CJC-1295 DAC dosage math?

The most common error is unit confusion, mg vs mcg, treating 1 mg as 100 mcg instead of 1000 mcg, which produces a 10x dosing error in either direction. The second most common is forgetting that DAC and no-DAC versions use completely different frequency schedules, so someone following a daily no-DAC protocol with a DAC product ends up dosing far more often than the drug's roughly 6.8-day half-life would call for ^[2][3]. A third mistake is not accounting for reconstitution volume changes between vials. If you switch from a 2 mg vial mixed with 2 mL to a 5 mg vial and mix it with the same 2 mL out of habit, the concentration is now 2.5x higher, and drawing your "usual" unit count delivers 2.5x the dose. A fourth, more subtle mistake is treating the weekly total as the per-injection amount. If a protocol calls for 2 mg per week split into two doses, the per-injection dose is 1 mg, not 2 mg twice. This single misread has probably caused more accidental overdosing in self-directed peptide use than any syringe error. Finally, people sometimes assume a calculator's default suggested dose is a validated clinical recommendation. It isn't. Any calculator, including good ones, is just doing the arithmetic on whatever target number you or a source you trust decided on.

What are the safety and quality issues that a calculator can't fix?

A dosage calculator solves an arithmetic problem. It says nothing about whether the vial actually contains what the label claims, whether it's sterile, or whether the dose you've chosen is appropriate given your health history. Because CJC-1295 sits outside FDA-approved manufacturing and outside the substances FDA has found appropriate for 503A compounding ^[1], there is no standardized batch testing requirement the way there is for an approved pharmaceutical. Quality varies by supplier, and independent testing of gray-market peptides has repeatedly found products with incorrect concentrations or purity issues, which is a separate risk from dosing math entirely. Any discussion of side effects, injection site reactions, water retention, changes in blood glucose, or the theoretical long-term risks of sustained IGF-1 elevation belongs in a dedicated safety review, not folded into a calculator explainer. Our cjc 1295 side effects page covers that ground directly. If you're earlier in the process and trying to figure out sourcing and how to evaluate a supplier before you ever open a calculator, that's covered on cjc 1295 for sale, including what provider-reviewed sourcing through a named pharmacy partner looks like versus buying from an unverified research-chemical seller. CJC-1295 Co doesn't compound or manufacture anything itself; the point of provider review is a clinician checking the dose and the source before anything gets used, which a calculator alone can never do.

Quick reference: common CJC-1295 DAC concentrations

Below is a reference table showing common reconstitution outcomes, purely for understanding the arithmetic, not as a recommendation for any specific dose. | Vial size | Water added | Concentration | mcg per unit (U-100 syringe) |

Frequently asked questions

What is a CJC-1295 DAC dosage calculator used for?

It converts a target peptide dose (in mcg or mg) into the syringe units you'd draw, based on vial size and how much bacteriostatic water you added. It's a unit-conversion tool, not a medical recommendation, and it can't validate whether your chosen dose or source is appropriate.

How many mg of CJC-1295 DAC are in a typical vial?

Common commercial vial sizes are 2 mg and 5 mg, though this varies by supplier since there's no FDA-approved formulation setting a standard. Always confirm the actual labeled amount before running any calculation, since assuming a size can cause a large dosing error.

What's the difference between CJC-1295 with DAC and without DAC for dosing?

DAC's albumin-binding extends its half-life to roughly 6.8 days, so it's dosed once or twice weekly at 1-2 mg total. No-DAC CJC-1295 has a half-life around 30 minutes and is typically dosed daily at 100-300 mcg per injection. Using the wrong schedule for the wrong version is a common dosing error ^[2][3].

How much bacteriostatic water should I add to CJC-1295 DAC?

There's no single correct answer; 1 mL or 2 mL per 2 mg vial are the most common choices, producing 20 mcg/unit or 10 mcg/unit respectively. Less water means smaller injection volumes but higher concentration, which raises the stakes of any syringe-reading error.

Why do people combine CJC-1295 DAC with ipamorelin?

CJC-1295 works through the GHRH receptor and ipamorelin through the ghrelin receptor, a different pathway, so the rationale is additive GH stimulation. This is mechanistic reasoning based on each peptide's individual pharmacology, not a dedicated randomized trial testing the combination's outcomes in humans ^[5][6].

Is CJC-1295 DAC FDA-approved?

No. CJC-1295 is not an FDA-approved drug for any human indication, and FDA's own bulk substance review placed it in Category 2, not recommended for use in 503A compounding ^[1]. Any product sold is outside standard pharmaceutical quality and safety oversight.

What half-life does CJC-1295 DAC actually have, according to research?

The original human pharmacokinetic study (Teichman et al., 2006, Journal of Clinical Endocrinology & Metabolism) reported an elimination half-life of approximately 6.8 days for the DAC-conjugated molecule, which is the basis for once or twice weekly dosing schedules ^[2][3].

Can a dosage calculator tell me if my CJC-1295 is real or contaminated?

No. A calculator only does the concentration math you feed it; it has no way to verify actual peptide content, purity, or sterility. That requires third-party lab testing or, in a supervised setting, sourcing through a provider-reviewed pharmacy pathway rather than an unverified seller.

How do I convert CJC-1295 DAC dose from mcg to syringe units?

Divide your target dose in mcg by the mcg-per-unit value of your reconstitution (total mcg in the vial divided by mL added, then divided by 100 units per mL). For example, 1000 mcg/mL reconstitution equals 10 mcg per unit, so a 500 mcg dose is 50 units.

What's the typical weekly dose range for CJC-1295 DAC discussed in available sources?

Most compounding and discussion sources cite 1-2 mg total per week, often split into two doses roughly 3-4 days apart. This does not directly match the 30-480 mcg/kg per-dose range used in the original clinical pharmacology study, so treat it as extrapolated practice, not confirmed clinical dosing ^[2][3].

Does reconstitution volume change how long CJC-1295 DAC stays potent?

Reconstitution volume changes concentration, not chemical stability. Stability is more affected by temperature and time; bacteriostatic water's 0.9% benzyl alcohol preservative supports a commonly cited 28-day refrigerated use window for multi-dose vials in general compounding practice, though exact peptide-specific stability data is limited ^[4].

Where can I find provider-reviewed CJC-1295 dosing guidance instead of forum numbers?

Look for sourcing pathways that route through licensed pharmacy partners with clinician review rather than direct research-chemical sellers. CJC-1295 Co's provider-reviewed model connects readers to a fulfilling pharmacy partner and clinical oversight rather than compounding or selling anything directly.

Sources

1. FDA, "Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act" (category determinations): CJC-1295 has been reviewed and placed in the category not recommended for use in 503A compounding
2. Teichman SL, et al., "Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults", Journal of Clinical Endocrinology & Metabolism, 2006: CJC-1295 DAC pharmacokinetics, half-life, and dose-dependent GH/IGF-1 increases in healthy adults
3. PubMed, Teichman et al. 2006, PMID 16352683: Single and multiple dose study details, half-life approximately 6.8 days, dose range 30-480 mcg/kg
4. DailyMed, Bacteriostatic Water for Injection, USP label: Bacteriostatic water contains 0.9% benzyl alcohol as a preservative used in multi-dose vial reconstitution
5. FDA, Macimorelin (Macrilen) approval, NDA 208979: Ghrelin receptor agonists are an established class of GH secretagogues distinct from GHRH analogues
6. Raun K, et al., ipamorelin pharmacology and postoperative human study, Journal of Clinical Endocrinology & Metabolism, 1998, PMID 9814527: Ipamorelin studied in humans as a growth hormone secretagogue with a distinct receptor mechanism from GHRH analogues